Market Overview

Monday Morning Movers (TEVA, QSFT, STZ)

Related TEVA
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
Vetr Issues Strong Buy As Teva Trends Down
The Vetr community has downgraded $TEVA to 3.5-Stars (Vetr)

Teva Pharmaceuticals (NYSE: TEVA): Teva traded up about 6.5% early in the session on Monday. Teva's patent for its drug Copaxone was upheld by a U.S. District Court. Momenta Pharmaceuticals (NADAQ: MNTA) challenged Teva's patent for its Multiple Sclerosis drug.

Dr. Jeremy Levin, Teva's President and Chief Executive Officer stated, “Teva is confident COPAXONE will remain a proprietary, global market leading product for the reduction of relapses in patients with RRMS over the product's lifecycle given the strength of its intellectual property rights.”

Quest Software (NASDAQ: QSFT): On Monday, Quest Software announced it had received a proposal from a strategic bidder to acquire all of the outstanding shares of Quest common stock for $27.50 per share in cash. Reuters reported that the bidder is Dell (NADAQ: DELL). Quest traded up about 5.5% early in the day on Monday.

Constellation Brands (NYSE: STZ): Constellation Brands, a producer and marketer of alcohol in the United States, traded up about 10% early on Monday. Anheuser-Busch InBev (NYSE: BUD) is in talks to take over Modelo, a Mexican brewer. Modelo brews Corona, and Constellations Brand is a distributer of Corona in the United States.

Posted-In: Long Ideas News Short Ideas Rumors FDA M&A Intraday Update Movers Best of Benzinga


Related Articles (QSFT + BUD)

View Comments and Join the Discussion!